Discovery of a Fluoroquinolone-Resistant Serratia marcescens Clinical Isolate without Quinolone Resistance-Determining Region Mutations
نویسندگان
چکیده
Sir, Serratia marcescens, once considered to be an innocuous and non-pathogenic organism, is now an important cause of hospitalacquired infections. This organism is associated with respiratory tract infections, urinary tract infections, septicemia, meningitis, and wound infections [1, 2]. S. marcescens infections are difficult to treat because of high resistance to a wide variety of antibiotics, including cephalosporins, fluoroquinolones, and aztreonam [2]. Fluoroquinolones are broad-spectrum bactericidal antimicrobial agents that are used to treat various bacterial infections. Although S. marcescens infections are frequently treated with fluoroquinolones, the incidence of fluoroquinolone resistance continues to increase in clinical settings in China [2]. Fluoroquinolone resistance is mainly caused by chromosomal mutations affecting the quinolone resistance-determining region (QRDR) of gyrA and gyrB, which encode DNA gyrase subunits, and parC and parE, which encode topoisomerase IV subunits [3]. Moreover, plasmid-mediated quinolone resistance (PMQR) genes have been reported in gram-negative bacteria, including S. marcescens, and include the qnr, qep, and oqx systems [4]. The major cause of fluoroquinolone resistance is chromosomal mutation. The acquisition of PMQR genes alone results in a low level of fluoroquinolone resistance and does not lead to minimum inhibitory concentrations (MICs) exceeding the threshold of these agents [3]. We isolated a S. marcescens strain, designated as GN0780, from the wound drainage fluid of a 66-yr-old male patient who had femoral fractures and was admitted to the Department of Orthopedics at the People’s Hospital of Huangshan (Huangshan, China) in 2011. The MICs of ciprofloxacin (CIP), levofloxacin (LVX), gatifloxacin (GAT), and nalidixic acid (NAL) exceeded the resistance thresholds proposed by the Clinical and Laboratory Standards Institute (2012) (Table 1) [5]. Surprisingly, direct DNA sequencing of the QRDRs did not reveal any mutations in
منابع مشابه
A fluoroquinolone-resistant Escherichia coli clinical isolate without quinolone resistance-determining region mutations found in Japan.
متن کامل
Cloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolates.
The sequence of the DNA gyrase gyrA gene of Serratia marcescens ATCC 14756 was determined. An open reading frame of 2,640 nucleotides coding for a polypeptide with a calculated molecular mass of 97,460 was found, and its sequence complemented the sequence of an Escherichia coli gyrA temperature-sensitive mutation. Analysis of the PCR products of the quinolone resistance-determining regions of g...
متن کاملQuinolone resistance in clinical isolates of Serratia marcescens.
The uptakes of norfloxacin by quinolone-resistant and -susceptible strains of Serratia marcescens were almost the same and 50% inhibitory concentrations for DNA gyrase and the MICs of quinolones were correlated, suggesting that DNA gyrase alterations are the basis of quinolone resistance.
متن کاملThe involvement of mutation in the serine 83 of quinolone resistant determining regions of the GyrA Gene in resistance to ciprofloxacin in Escherichia coli .
Appearance of bacteria resistant to antibacterial agents puts physicians in trouble and threatens the health of the world. The rapid development of bacterial resistance in Escherichia coli to ciprofloxacin makes difficult the treatment of infectious diseases. So, detection of the locations of possible mutations in gyrase A gene ( gyrA ) in these mutants is very important to determine the mech...
متن کاملgyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.
Fluoroquinolone resistance (FQ-R) in clinical isolates of Enterobacteriaceae species has been reported with increasing frequency in recent years. Two mechanisms of FQ-R have been identified in gram-negative organisms: mutations in DNA gyrase and reduced intracellular drug accumulation. A single point mutation in gyrA has been shown to reduce susceptibility to fluoroquinolones. To determine the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 34 شماره
صفحات -
تاریخ انتشار 2014